For Immediate Release
2010
EGI Reports Solid Growth in 2009
Despite challenging economic conditions, 2009 was EGI’s best year ever. Net sales were $8.2 M. Total revenues reached $9.5 M, with a modestly profitable bottom line. This strong performance represents a 10% growth in sales over the prior year. International sales, particularly in the European Union and Asia, rose sharply and accounted for approximately 50% of EGI’s total net sales in 2009.
Important to EGI’s strong momentum in 2009 was the announcement of a number of new products, including GES 300 MR, which is the world’s first truly high channel count EEG system for use in MR environments, and the new GEM product line for ambulatory and routine EEG applications.
Critical to EGI’s success is the success of our customers. In 2009, EGI’s clinical and research customers published their work in more than 150 articles in peer-reviewed journals. Particularly exciting was the growth in the number of clinical publications employing EGI technology in core clinical applications, such as epilepsy, pre surgical planning, and autism.
In addition to customer publications, customers have supported EGI with their overall customer satisfaction, professional referral rate, continued reorders, and constructive clinical and research feedback for certified and beta products. Commenting on EGI’s 2009 success, EGI President Dr Ann Bunnenberg said, “The strong support we received from our research and clinical customers worldwide in 2009 has put EGI in a strong position to continue reinvesting to expand its product line, support, and training capabilities.”
“EGI’s continuing investment in new product development and feature enhancement for existing products will result in a rich stream of product releases and new features for our customers in the upcoming months,” Dr. Bunnenberg added. “We at EGI deeply appreciate the support of the international neurology and neuroscience communities in making it possible for EGI to continue to grow even during a difficult economic period.”
In 2010, EGI will continue to engage in research that leads to innovative products for EEG and advanced brain imaging. The success of EGI scientists in securing funding from the National Institutes of Health, Department of Defense, and Small Business Innovation Research programs will allow aggressive innovation to support new products. EGI customers can expect a regular progression of upgrades and advances to keep them on the cutting edge of scientific technology.
Archives
2008
Electrical Geodesics, Inc. (EGI) Licenses Key Technology for EEG/fMRI Recording from UCLA
Eugene, Oregon - November 18, 2008 - New techniques for imaging the functional activity of the human brain by simultaneously recording changes in its electrical activity (EEG) and blood flow (fMRI) are contributing important insights into normal and pathological brain functioning. However, the EEG signal recorded with existing EEG/fMRI technologies is often of disappointing quality.
Today, EGI announced that it had licensed a key patent from The Regents of the University of California covering methods for improving the signal quality of the EEG when it is recorded during an MRI exam (U.S. Patent No. 7,286,871, “Method and apparatus for reducing contamination of an electrical signal”). The licensed techniques, developed by Dr. Mark Cohen of UCLA’s David Geffen School of Medicine, allow the artifact introduced into the recorded EEG signal by the large gradient pulses emitted by the MRI during its normal operation to be effectively removed from the data using timing pulses generated by the MRI. Additional claims in the patent protect the use of “twisted” pairs electrodes to help improve the signal-to-noise ratio, which also results in cleaner EEG recordings.
Commenting on the importance of the Cohen patent, Dr. Don Tucker, CEO and Chief Scientist of EGI said, "Low noise recordings are essential to allow EEG source localization for the MR-registered recordings. The UCLA technology provides a unique and effective method of noise cancellation in the MR environment."
EGI plans to incorporate the licensed technology in its announced Q-1 2009 release of the world’s first truly high-density MRI compatible EEG system: the 256- and 128-electrode Geodesic EEG System (GES) 300-MR. This new high-density EEG/fMRI system will be available as an upgrade package to its existing, industry-leading dense array EEG system (dEEG), the GES 300. Ann Bunnenberg, President of EGI noted, “EGI is particularly pleased to make this important new technology available to all of our current GES 300 system customers.”
Based in Eugene, Oregon, EGI is the leading developer and manufacturer of dEEG systems for medicine, neurosurgery, and neuroscience research worldwide. Additional background information on EGI is available at www.egi.com.
|